PT2595485T - Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma - Google Patents

Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma

Info

Publication number
PT2595485T
PT2595485T PT118103506T PT11810350T PT2595485T PT 2595485 T PT2595485 T PT 2595485T PT 118103506 T PT118103506 T PT 118103506T PT 11810350 T PT11810350 T PT 11810350T PT 2595485 T PT2595485 T PT 2595485T
Authority
PT
Portugal
Prior art keywords
methods
amide derivatives
receptor mediated
mediated disorders
cyclic amide
Prior art date
Application number
PT118103506T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PT2595485T publication Critical patent/PT2595485T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT118103506T 2010-07-20 2011-07-20 Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma PT2595485T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36608010P 2010-07-20 2010-07-20

Publications (1)

Publication Number Publication Date
PT2595485T true PT2595485T (pt) 2022-05-30

Family

ID=45497167

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118103506T PT2595485T (pt) 2010-07-20 2011-07-20 Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma

Country Status (15)

Country Link
US (4) US20130274290A1 (enExample)
EP (2) EP4070794A3 (enExample)
JP (3) JP2013531073A (enExample)
KR (1) KR101867634B1 (enExample)
CN (2) CN107007603A (enExample)
BR (1) BR112013001302A2 (enExample)
CA (2) CA3154027A1 (enExample)
DK (1) DK2595485T3 (enExample)
ES (1) ES2914120T3 (enExample)
HU (1) HUE058736T2 (enExample)
PL (1) PL2595485T3 (enExample)
PT (1) PT2595485T (enExample)
RU (2) RU2613201C2 (enExample)
TW (1) TWI520949B (enExample)
WO (1) WO2012012543A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
WO2015191554A1 (en) * 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
BR112017011555B1 (pt) 2014-12-02 2023-10-03 Minerva Neurosciences, Inc Formulação farmacêutica compreendendo 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1- ona e kit
SG11201810358YA (en) * 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
BR112019027398A2 (pt) * 2017-06-21 2020-07-07 Minerva Neurosciences, Inc. formas de dosagem orais de liberação controlada gastrorresistente
WO2020041504A1 (en) * 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
JP2023526515A (ja) 2020-05-20 2023-06-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ リソソーム蓄積症をヒスタチンペプチドで処置するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908641B (en) * 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
IE903857A1 (en) * 1989-10-27 1991-05-08 Du Pont Merck Pharma (N-Phthalimidoalkyl)Piperidines
EP0637306B1 (en) * 1992-04-23 2001-05-30 Merrell Pharmaceuticals Inc. 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy
ATE366249T1 (de) * 2000-02-29 2007-07-15 Mitsubishi Pharma Corp Zyklische amid-derivate
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
TWI520949B (zh) 2016-02-11
HUE058736T2 (hu) 2022-09-28
JP2016199578A (ja) 2016-12-01
JP2018065829A (ja) 2018-04-26
EP4070794A2 (en) 2022-10-12
TW201211022A (en) 2012-03-16
RU2017105262A (ru) 2019-01-18
RU2017105262A3 (enExample) 2019-01-18
CN103108548A (zh) 2013-05-15
CA2805904A1 (en) 2012-01-26
KR101867634B1 (ko) 2018-06-15
EP2595485A4 (en) 2014-04-23
EP4070794A3 (en) 2023-01-18
US20250228838A1 (en) 2025-07-17
US20160354357A1 (en) 2016-12-08
PL2595485T3 (pl) 2022-06-20
RU2013107378A (ru) 2014-08-27
CN107007603A (zh) 2017-08-04
US20130274290A1 (en) 2013-10-17
US20210106573A1 (en) 2021-04-15
KR20130129906A (ko) 2013-11-29
RU2613201C2 (ru) 2017-03-15
CA2805904C (en) 2022-06-21
JP6419294B2 (ja) 2018-11-07
CA3154027A1 (en) 2012-01-26
JP2013531073A (ja) 2013-08-01
RU2746871C2 (ru) 2021-04-21
EP2595485A1 (en) 2013-05-29
ES2914120T3 (es) 2022-06-07
EP2595485B1 (en) 2022-03-16
DK2595485T3 (da) 2022-05-30
BR112013001302A2 (pt) 2017-07-04
WO2012012543A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
CO6880066A2 (es) Composición farmacéutica de sabor enmascarado
PT2595485T (pt) Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma
BR112013019211A2 (pt) amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon
BR112014001453A2 (pt) aditivo catalizador e método de preparação do mesmo
SI2707029T1 (sl) Metode zdravljenja ali preprečevanja s holesterolom povezanih motenj
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
CL2014003531A1 (es) Suministro de farmaco diodegradable para las composiciones hidrofóbicas y su metodo de preparacion.
EP2763936A4 (en) FAST SYNTHESIS OF GRAPHS AND FORMATION OF GRAPHIC STRUCTURES
CR20130192A (es) Derivados de bencimidazol como inhibidores de cinasa p13
IL235811A0 (en) Converted pyrazoloquinazolinones and pyrroloquiazolinones as allosteric modulators of group ii metabotropic glutamate receptors
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
CO6950474A2 (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostéricos negativos de mglur2, composiciones, y su uso
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
PL2937094T3 (pl) Kompozycja farmaceutyczna do leczenia bólu głowy i sposób jej przygotowania
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
BR112014010339A2 (pt) método para produzir biocombustíveis via tratamento hidrocatalítico de fase orgânica de biomassa
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
IL232190A0 (en) A method for treating inflammatory diseases by anti-m-csf antibodies
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
EP2690972A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2603490A4 (en) NEW TRPV3 MODULATORS
EP2671572A4 (en) PLASTER AND PAVER MAKING
CO6980661A2 (es) Derivados de n-(4-quinolinilmetil) sulfonamiday su uso como antihelminticos